These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 11795430

  • 1. Development of Bowman-Birk inhibitor for chemoprevention of oral head and neck cancer.
    Meyskens FL.
    Ann N Y Acad Sci; 2001 Dec; 952():116-23. PubMed ID: 11795430
    [Abstract] [Full Text] [Related]

  • 2. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment.
    Armstrong WB, Wan XS, Kennedy AR, Taylor TH, Meyskens FL.
    Laryngoscope; 2003 Oct; 113(10):1687-702. PubMed ID: 14520092
    [Abstract] [Full Text] [Related]

  • 3. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial.
    Armstrong WB, Kennedy AR, Wan XS, Taylor TH, Nguyen QA, Jensen J, Thompson W, Lagerberg W, Meyskens FL.
    Clin Cancer Res; 2000 Dec; 6(12):4684-91. PubMed ID: 11156220
    [Abstract] [Full Text] [Related]

  • 4. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia.
    Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE, Meyskens FL.
    Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):43-7. PubMed ID: 10667462
    [Abstract] [Full Text] [Related]

  • 5. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial.
    Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, Le AD, Perloff M, Civantos F, Goodwin WJ, Wirth LJ, Kerr AR, Meyskens FL.
    Cancer Prev Res (Phila); 2013 May; 6(5):410-8. PubMed ID: 23639862
    [Abstract] [Full Text] [Related]

  • 6. Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk Inhibitor.
    Wan XS, Meyskens FL, Armstrong WB, Taylor TH, Kennedy AR.
    Cancer Epidemiol Biomarkers Prev; 1999 Jul; 8(7):601-8. PubMed ID: 10428197
    [Abstract] [Full Text] [Related]

  • 7. The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent.
    Kennedy AR.
    Am J Clin Nutr; 1998 Dec; 68(6 Suppl):1406S-1412S. PubMed ID: 9848508
    [Abstract] [Full Text] [Related]

  • 8. Optimizing biomarkers and endpoints in oral cancer chemoprevention trials.
    William WN, Papadimitrakopoulou VA.
    Cancer Prev Res (Phila); 2013 May; 6(5):375-8. PubMed ID: 23639861
    [Abstract] [Full Text] [Related]

  • 9. Detection of Bowman-Birk inhibitor and anti-Bowman-Birk inhibitor antibodies in sera of humans and animals treated with Bowman-Birk inhibitor concentrate.
    Wan XS, Serota DG, Ware JH, Crowell JA, Kennedy AR.
    Nutr Cancer; 2002 May; 43(2):167-73. PubMed ID: 12588697
    [Abstract] [Full Text] [Related]

  • 10. Oral Cancer Chernoprevention: Current Status and Future Direction.
    Messadi DV, Sato K.
    J Calif Dent Assoc; 2016 Feb; 44(2):101-11. PubMed ID: 26930753
    [Abstract] [Full Text] [Related]

  • 11. Bowman-Birk inhibitors from legumes as colorectal chemopreventive agents.
    Clemente A, Arques Mdel C.
    World J Gastroenterol; 2014 Aug 14; 20(30):10305-15. PubMed ID: 25132747
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Development of difluoromethyl-ornithine and Bowman-Birk inhibitor as chemopreventive agents by assessment of relevant biomarker modulation: some lessons learned.
    Meyskens FL.
    IARC Sci Publ; 2001 Aug 14; 154():49-55. PubMed ID: 11220668
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Retinoid modulation of biomarkers in oral leukoplakia/dysplasia.
    Beenken SW, Huang P, Sellers M, Peters G, Listinsky C, Stockard C, Hubbard W, Wheeler R, Grizzle W.
    J Cell Biochem Suppl; 1994 Aug 14; 19():270-7. PubMed ID: 7823600
    [Abstract] [Full Text] [Related]

  • 16. Proteases, protease inhibitors and radiation carcinogenesis.
    Kennedy AR.
    Int J Radiat Biol; 2023 Aug 14; 99(6):882-890. PubMed ID: 34325613
    [Abstract] [Full Text] [Related]

  • 17. Effects of Bowman-Birk inhibitor on rat colon carcinogenesis.
    Kennedy AR, Billings PC, Wan XS, Newberne PM.
    Nutr Cancer; 2002 Aug 14; 43(2):174-86. PubMed ID: 12588698
    [Abstract] [Full Text] [Related]

  • 18. Cancer prevention by protease inhibitors.
    Kennedy AR.
    Prev Med; 1993 Sep 14; 22(5):796-811. PubMed ID: 8234219
    [Abstract] [Full Text] [Related]

  • 19. Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia.
    Malkowicz SB, McKenna WG, Vaughn DJ, Wan XS, Propert KJ, Rockwell K, Marks SH, Wein AJ, Kennedy AR.
    Prostate; 2001 Jun 15; 48(1):16-28. PubMed ID: 11391683
    [Abstract] [Full Text] [Related]

  • 20. The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis.
    Gran B, Tabibzadeh N, Martin A, Ventura ES, Ware JH, Zhang GX, Parr JL, Kennedy AR, Rostami AM.
    Mult Scler; 2006 Dec 15; 12(6):688-97. PubMed ID: 17262995
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.